Pipeline of Key Proprietary Products

Our pipeline of key proprietary products includes late-stage drug candidates for patients with multiple sclerosis and schizophrenia, and an early-stage drug candidate in immuno-oncology.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 NDA Filed
ALKS 3831

Diroximel Fumarate (BIIB098)*
(Multiple Sclerosis)

ALKS 4230

*In development under a license and collaboration agreement with Biogen.

Learn more about our portfolio of innovative products.